Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer

doi:10.1056/NEJMoa061884

Volume 355:2542-2550		December 14, 2006		Number 24

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, M.D., Robert Gray, Ph.D., Michael C. Perry, M.D., Julie Brahmer, M.D., Joan H. Schiller, M.D., Afshin Dowlati, M.D., Rogerio Lilenbaum, M.D., and David H. Johnson, M.D.

Full Text

PDF

PDA Full Text

PowerPoint Slide Set

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

ABSTRACT

Background Bevacizumab, a monoclonal antibody against vascularendothelial growth factor, has been shown to benefit patientswith a variety of cancers.

Methods Between July 2001 and April 2004, the Eastern CooperativeOncology Group (ECOG) conducted a randomized study in which878 patients with recurrent or advanced non–small-celllung cancer (stage IIIB or IV) were assigned to chemotherapywith paclitaxel and carboplatin alone (444) or paclitaxel andcarboplatin plus bevacizumab (434). Chemotherapy was administeredevery 3 weeks for six cycles, and bevacizumab was administeredevery 3 weeks until disease progression was evident or toxiceffects were intolerable. Patients with squamous-cell tumors,brain metastases, clinically significant hemoptysis, or inadequateorgan function or performance status (ECOG performance status,>1) were excluded. The primary end point was overall survival.

Results The median survival was 12.3 months in the group assignedto chemotherapy plus bevacizumab, as compared with 10.3 monthsin the chemotherapy-alone group (hazard ratio for death, 0.79;P=0.003). The median progression-free survival in the two groupswas 6.2 and 4.5 months, respectively (hazard ratio for diseaseprogression, 0.66; P<0.001), with corresponding responserates of 35% and 15% (P<0.001). Rates of clinically significantbleeding were 4.4% and 0.7%, respectively (P<0.001). Therewere 15 treatment-related deaths in the chemotherapy-plus-bevacizumabgroup, including 5 from pulmonary hemorrhage.

Conclusions The addition of bevacizumab to paclitaxel plus carboplatinin the treatment of selected patients with non–small-celllung cancer has a significant survival benefit with the riskof increased treatment-related deaths. (ClinicalTrials.gov number,NCT00021060 [ClinicalTrials.gov] .)

Source Information

From Vanderbilt University, Nashville (A.S., D.H.J.); the Dana–Farber Cancer Institute, Boston (R.G.); the Ellis Fischel Cancer Center, University of Missouri, Columbia (M.C.P.); Johns Hopkins University, Baltimore (J.B.); the University of Wisconsin, Madison (J.H.S.); University Hospitals of Cleveland, Cleveland (A.D.); and Mount Sinai Hospital, Miami (R.L.).

Address reprint requests to Dr. Sandler at the Vanderbilt–Ingram Cancer Center, 2220 Pierce Ave., Nashville, TN 37232, or at alan.sandler{at}vanderbilt.edu.

Full Text of this Article

This article has been cited by other articles:

Sundaram, S., Trivedi, R., Durairaj, C., Ramesh, R., Ambati, B. K., Kompella, U. B. (2009). Targeted Drug and Gene Delivery Systems for Lung Cancer Therapy. Clin. Cancer Res. 15: 7299-7308 [Abstract] [Full Text]
Tabernero, J., Macarulla, T. (2009). Changing the Paradigm in Conducting Randomized Clinical Studies in Advanced Pancreatic Cancer: An Opportunity for Better Clinical Development. JCO 27: 5487-5491 [Full Text]
Perez, E. A., Hillman, D. W., Dentchev, T., Le-Lindqwister, N. A., Geeraerts, L. H., Fitch, T. R., Liu, H., Graham, D. L., Kahanic, S. P., Gross, H. M., Patel, T. A., Palmieri, F. M., Dueck, A. C. (2009). North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol 0: mdp512v1-mdp512 [Abstract] [Full Text]
Dorff, T. B., Goldkorn, A., Quinn, D. I. (2009). Review: Targeted therapy in renal cancer. Therapeutic Advances in Medical Oncology 1: 183-205 [Abstract]
Socinski, M. A., Langer, C. J., Huang, J. E., Kolb, M. M., Compton, P., Wang, L., Akerley, W. (2009). Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases. JCO 27: 5255-5261 [Abstract] [Full Text]
Lee, S. M., Rudd, R., Woll, P. J., Ottensmeier, C., Gilligan, D., Price, A., Spiro, S., Gower, N., Jitlal, M., Hackshaw, A. (2009). Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. JCO 27: 5248-5254 [Abstract] [Full Text]
O'Connor, J. P.B., Carano, R. A.D., Clamp, A. R., Ross, J., Ho, C. C.K., Jackson, A., Parker, G. J.M., Rose, C. J., Peale, F. V., Friesenhahn, M., Mitchell, C. L., Watson, Y., Roberts, C., Hope, L., Cheung, S., Reslan, H. B., Go, M. A. T., Pacheco, G. J., Wu, X., Cao, T. C., Ross, S., Buonaccorsi, G. A., Davies, K., Hasan, J., Thornton, P., del Puerto, O., Ferrara, N., van Bruggen, N., Jayson, G. C. (2009). Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging. Clin. Cancer Res. 15: 6674-6682 [Abstract] [Full Text]
Steeghs, N., Rabelink, T. J., op 't Roodt, J., Batman, E., Cluitmans, F. H. M., Weijl, N. I., de Koning, E., Gelderblom, H. (2009). Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 0: mdp417v1-mdp417 [Abstract] [Full Text]
Sorrentino, C., Di Carlo, E. (2009). Expression of IL-32 in Human Lung Cancer Is Related to the Histotype and Metastatic Phenotype. Am. J. Respir. Crit. Care Med. 180: 769-779 [Abstract] [Full Text]
Sakakibara, T., Inoue, A., Sugawara, S., Maemondo, M., Ishida, T., Usui, K., Abe, T., Kanbe, M., Watanabe, H., Saijo, Y., Nukiwa, T. (2009). Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 0: mdp401v1-mdp401 [Abstract] [Full Text]
West, H., Harpole, D., Travis, W. (2009). Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer. Chest 136: 1112-1118 [Abstract] [Full Text]
Maitland, M. L., Kasza, K. E., Karrison, T., Moshier, K., Sit, L., Black, H. R., Undevia, S. D., Stadler, W. M., Elliott, W. J., Ratain, M. J. (2009). Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment. Clin. Cancer Res. 15: 6250-6257 [Abstract] [Full Text]
Rini, B. I., Garcia, J. A., Cooney, M. M., Elson, P., Tyler, A., Beatty, K., Bokar, J., Mekhail, T., Bukowski, R.M., Budd, G. T., Triozzi, P., Borden, E., Ivy, P., Chen, H. X., Dowlati, A., Dreicer, R. (2009). A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors. Clin. Cancer Res. 15: 6277-6283 [Abstract] [Full Text]
Wilcox, R. A., Wada, D. A., Ziesmer, S. C., Elsawa, S. F., Comfere, N. I., Dietz, A. B., Novak, A. J., Witzig, T. E., Feldman, A. L., Pittelkow, M. R., Ansell, S. M. (2009). Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114: 2936-2944 [Abstract] [Full Text]
Giaccone, G., Zatloukal, P., Roubec, J., Floor, K., Musil, J., Kuta, M., van Klaveren, R. J., Chaudhary, S., Gunther, A., Shamsili, S. (2009). Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-Small-Cell Lung Cancer. JCO 27: 4481-4486 [Abstract] [Full Text]
Cappuzzo, F., Tallini, G., Finocchiaro, G., Wilson, R. S., Ligorio, C., Giordano, L., Toschi, L., Incarbone, M., Cavina, R., Terracciano, L., Roncalli, M., Alloisio, M., Varella-Garcia, M., Franklin, W. A., Santoro, A. (2009). Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 0: mdp357v1-mdp357 [Abstract] [Full Text]
Rudin, C. M., Avila-Tang, E., Harris, C. C., Herman, J. G., Hirsch, F. R., Pao, W., Schwartz, A. G., Vahakangas, K. H., Samet, J. M. (2009). Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. Clin. Cancer Res. 15: 5646-5661 [Abstract] [Full Text]
Blumenschein, G. R. Jr, Gatzemeier, U., Fossella, F., Stewart, D. J., Cupit, L., Cihon, F., O'Leary, J., Reck, M. (2009). Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer. JCO 27: 4274-4280 [Abstract] [Full Text]
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., Settleman, J., Kobayashi, S., Mark, E. J., Rodig, S. J., Chirieac, L. R., Kwak, E. L., Lynch, T. J., Iafrate, A. J. (2009). Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. JCO 27: 4247-4253 [Abstract] [Full Text]
Horn, L., Pao, W. (2009). EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer. JCO 27: 4232-4235 [Full Text]
Lind, J. S.W., Smit, E. F. (2009). Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology 1: 95-107 [Abstract]
Bepler, G. (2009). Are We Coming Full Circle for Lung Cancer Screening a Second Time?. Am. J. Respir. Crit. Care Med. 180: 384-385 [Full Text]
Okita, N. T., Yamada, Y., Takahari, D., Hirashima, Y., Matsubara, J., Kato, K., Hamaguchi, T., Shirao, K., Shimada, Y., Taniguchi, H., Shimoda, T. (2009). Vascular Endothelial Growth Factor Receptor Expression as a Prognostic Marker for Survival in Colorectal Cancer. Jpn J Clin Oncol 39: 595-600 [Abstract] [Full Text]
Wozniak, A. J., Gadgeel, S. M. (2009). Review: Adjuvant therapy for resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology 1: 109-118 [Abstract]
Crane, C. H., Winter, K., Regine, W. F., Safran, H., Rich, T. A., Curran, W., Wolff, R. A., Willett, C. G. (2009). Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411. JCO 27: 4096-4102 [Abstract] [Full Text]
Eskens, F. A.L.M., Steeghs, N., Verweij, J., Bloem, J. L., Christensen, O., van Doorn, L., Ouwerkerk, J., de Jonge, M. J.A., Nortier, J. W.R., Kraetzschmar, J., Rajagopalan, P., Gelderblom, H. (2009). Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor {beta}, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors. JCO 27: 4169-4176 [Abstract] [Full Text]
Chien, A. J., Illi, J. A., Ko, A. H., Korn, W. M., Fong, L., Chen, L.-m., Kashani-Sabet, M., Ryan, C. J., Rosenberg, J. E., Dubey, S., Small, E. J., Jahan, T. M., Hylton, N. M., Yeh, B. M., Huang, Y., Koch, K. M., Moasser, M. M. (2009). A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies. Clin. Cancer Res. 15: 5569-5575 [Abstract] [Full Text]
Pao, W., Kris, M. G., Iafrate, A. J., Ladanyi, M., Janne, P. A., Wistuba, I. I., Miake-Lye, R., Herbst, R. S., Carbone, D. P., Johnson, B. E., Lynch, T. J. (2009). Integration of Molecular Profiling into the Lung Cancer Clinic. Clin. Cancer Res. 15: 5317-5322 [Abstract] [Full Text]
Pallis, A. G., Gridelli, C., van Meerbeeck, J. P., Greillier, L., Wedding, U., Lacombe, D., Welch, J., Belani, C. P., Aapro, M. (2009). EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol 0: mdp360v1-mdp360 [Abstract] [Full Text]
Takano, A., Ishikawa, N., Nishino, R., Masuda, K., Yasui, W., Inai, K., Nishimura, H., Ito, H., Nakayama, H., Miyagi, Y., Tsuchiya, E., Kohno, N., Nakamura, Y., Daigo, Y. (2009). Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer. Cancer Res. 69: 6694-6703 [Abstract] [Full Text]
Horn, L., Sandler, A. (2009). Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer. Clin. Cancer Res. 15: 5040-5048 [Abstract] [Full Text]
Schiller, J. H., Larson, T., Ou, S.-H. I., Limentani, S., Sandler, A., Vokes, E., Kim, S., Liau, K., Bycott, P., Olszanski, A. J., von Pawel, J. (2009). Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study. JCO 27: 3836-3841 [Abstract] [Full Text]
Fojo, T., Grady, C. (2009). How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI J Natl Cancer Inst 101: 1044-1048 [Abstract] [Full Text]
Patel, J. D., Hensing, T. A., Rademaker, A., Hart, E. M., Blum, M. G., Milton, D. T., Bonomi, P. D. (2009). Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer. JCO 27: 3284-3289 [Abstract] [Full Text]
Socinski, M. A. (2009). Re-Evaluating Duration of Therapy in Advanced Non-Small-Cell Lung Cancer: Is It Really Duration or Is It More About Timing and Exposure?. JCO 27: 3268-3270 [Full Text]
Schettino, C., Bareschino, M. A., Rossi, A., Maione, P., Castaldo, V., Mazzeo, N., Sacco, P. C., Ferrara, M. L., Palazzolo, G., Ciardiello, F., Gridelli, C. (2009). Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology 1: 5-13 [Abstract]
Larkin, J. M.G., Kipps, E. L.S., Powell, C. J., Swanton, C. (2009). Review: Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology 1: 15-27 [Abstract]
SHINGYOJI, M., ANDO, S., NISHIMURA, H., NAKAJIMA, T., ISHIKAWA, A., ITAKURA, M., IIZASA, T., KIMURA, H. (2009). VEGF in Patients with Non-small Cell Lung Cancer during Combination Chemotherapy of Carboplatin and Paclitaxel. Anticancer Res 29: 2635-2639 [Abstract] [Full Text]
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., Anver, M. R., Shoemaker, R. H., Melillo, G. (2009). Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Molecular Cancer Therapeutics 8: 1867-1877 [Abstract] [Full Text]
Banerjee, S., Gore, M. (2009). The Future of Targeted Therapies in Ovarian Cancer. The Oncologist 14: 706-716 [Abstract] [Full Text]
Ichihara, E., Ohashi, K., Takigawa, N., Osawa, M., Ogino, A., Tanimoto, M., Kiura, K. (2009). Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo. Cancer Res. 69: 5091-5098 [Abstract] [Full Text]
Shord, S. S., Bressler, L. R., Tierney, L. A., Cuellar, S., George, A. (2009). Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 66: 999-1013 [Abstract] [Full Text]
Rossi, G., Pelosi, G., Graziano, P., Barbareschi, M., Papotti, M. (2009). Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non--Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. INT J SURG PATHOL 17: 206-218 [Abstract]
RICE, S. D., BUSH, J. E., BROWER, S. L. (2009). Assessment of Erlotinib in Chemoresponse Assay. Anticancer Res 29: 1993-1997 [Abstract] [Full Text]
Courtwright, A., Siamakpour-Reihani, S., Arbiser, J. L., Banet, N., Hilliard, E., Fried, L., Livasy, C., Ketelsen, D., Nepal, D. B., Perou, C. M., Patterson, C., Klauber-DeMore, N. (2009). Secreted Frizzle-Related Protein 2 Stimulates Angiogenesis via a Calcineurin/NFAT Signaling Pathway. Cancer Res. 69: 4621-4628 [Abstract] [Full Text]
Chi, A. S., Sorensen, A. G., Jain, R. K., Batchelor, T. T. (2009). Angiogenesis as a Therapeutic Target in Malignant Gliomas. The Oncologist 14: 621-636 [Abstract] [Full Text]
Natale, R. B., Bodkin, D., Govindan, R., Sleckman, B. G., Rizvi, N. A., Capo, A., Germonpre, P., Eberhardt, W. E.E., Stockman, P. K., Kennedy, S. J., Ranson, M. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. JCO 27: 2523-2529 [Abstract] [Full Text]
Karp, D. D., Paz-Ares, L. G., Novello, S., Haluska, P., Garland, L., Cardenal, F., Blakely, L. J., Eisenberg, P. D., Langer, C. J., Blumenschein, G. Jr, Johnson, F. M., Green, S., Gualberto, A. (2009). Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer. JCO 27: 2516-2522 [Abstract] [Full Text]
Hanrahan, E. O., Ryan, A. J., Mann, H., Kennedy, S. J., Langmuir, P., Natale, R. B., Herbst, R. S., Johnson, B. E., Heymach, J. V. (2009). Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer. Clin. Cancer Res. 15: 3600-3609 [Abstract] [Full Text]
Naumov, G. N., Nilsson, M. B., Cascone, T., Briggs, A., Straume, O., Akslen, L. A., Lifshits, E., Byers, L. A., Xu, L., Wu, H.-k., Janne, P., Kobayashi, S., Halmos, B., Tenen, D., Tang, X. M., Engelman, J., Yeap, B., Folkman, J., Johnson, B. E., Heymach, J. V. (2009). Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance. Clin. Cancer Res. 15: 3484-3494 [Abstract] [Full Text]
Goss, G., Ferry, D., Wierzbicki, R., Laurie, S. A., Thompson, J., Biesma, B., Hirsch, F. R., Varella-Garcia, M., Duffield, E., Ataman, O. U., Zarenda, M., Armour, A. A. (2009). Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status. JCO 27: 2253-2260 [Abstract] [Full Text]
Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., Spano, J. P. (2009). Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20: 807-815 [Abstract] [Full Text]
McDermott, U., Ames, R. Y., Iafrate, A. J., Maheswaran, S., Stubbs, H., Greninger, P., McCutcheon, K., Milano, R., Tam, A., Lee, D. Y., Lucien, L., Brannigan, B. W., Ulkus, L. E., Ma, X.-J., Erlander, M. G., Haber, D. A., Sharma, S. V., Settleman, J. (2009). Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-{alpha} Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors. Cancer Res. 69: 3937-3946 [Abstract] [Full Text]
HIROSE, T., SUGIYAMA, T., KUSUMOTO, S., SHIRAI, T., NAKASHIMA, M., YAMAOKA, T., OKUDA, K., OGURA, K., OHNISHI, T., OHMORI, T., ADACHI, M. (2009). Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer. Anticancer Res 29: 1733-1738 [Abstract] [Full Text]
Ren, H., Chu, Z., Mao, L. (2009). Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Molecular Cancer Therapeutics 8: 1106-1112 [Abstract] [Full Text]
Savci-Heijink, C. D., Kosari, F., Aubry, M.-C., Caron, B. L., Sun, Z., Yang, P., Vasmatzis, G. (2009). The Role of Desmoglein-3 in the Diagnosis of Squamous Cell Carcinoma of the Lung. Am. J. Pathol. 174: 1629-1637 [Abstract] [Full Text]
Grossi, F., Aita, M., Defferrari, C., Rosetti, F., Brianti, A., Fasola, G., Vinante, O., Pronzato, P., Pappagallo, G. (2009). Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. The Oncologist 14: 497-510 [Abstract] [Full Text]
D'Addario, G., Felip, E., On behalf of the ESMO Guidelines Working Group, (2009). Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv68-iv70 [Full Text]
Lebanony, D., Benjamin, H., Gilad, S., Ezagouri, M., Dov, A., Ashkenazi, K., Gefen, N., Izraeli, S., Rechavi, G., Pass, H., Nonaka, D., Li, J., Spector, Y., Rosenfeld, N., Chajut, A., Cohen, D., Aharonov, R., Mansukhani, M. (2009). Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non-Small-Cell Lung Carcinoma. JCO 27: 2030-2037 [Abstract] [Full Text]
Chhatwani, L., Cabebe, E., Wakelee, H. A. (2009). Adjuvant Treatment of Resected Lung Cancer. Proc Am Thorac Soc 6: 194-200 [Abstract] [Full Text]
Horn, L., Sandler, A. B. (2009). Angiogenesis in the Treatment of Non-Small Cell Lung Cancer. Proc Am Thorac Soc 6: 206-217 [Abstract] [Full Text]
Dy, G. K., Adjei, A. A. (2009). Emerging Therapeutic Targets in Non-Small Cell Lung Cancer. Proc Am Thorac Soc 6: 218-223 [Abstract] [Full Text]
Stinchcombe, T. E., Socinski, M. A. (2009). Current Treatments for Advanced Stage Non-Small Cell Lung Cancer. Proc Am Thorac Soc 6: 233-241 [Abstract] [Full Text]
Minor, D. R. (2009). Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients. JAMA 301: 1434-1434 [Full Text]
Sculier, J-P., Moro-Sibilot, D. (2009). First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 33: 915-930 [Abstract] [Full Text]
Sartori, G., Cavazza, A., Sgambato, A., Marchioni, A., Barbieri, F., Longo, L., Bavieri, M., Murer, B., Meschiari, E., Tamberi, S., Cadioli, A., Luppi, F., Migaldi, M., Rossi, G. (2009). EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors. Am J Clin Pathol 131: 478-489 [Abstract] [Full Text]
Barros Costa, R. L. (2009). Review Article: Targeted Therapy: Comprehensive Review. AM J HOSP PALLIAT CARE 26: 137-146 [Abstract]
Korn, E. L., Freidlin, B., Mooney, M. (2009). Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005. JCO 27: 1712-1721 [Abstract] [Full Text]
Ramalingam, S. S., Khuri, F. R. (2009). The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer. The Oncologist 14: 412-424 [Abstract] [Full Text]
Pennell, N. A., Lynch, T. J. Jr. (2009). Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC. The Oncologist 14: 399-411 [Abstract] [Full Text]
Sandler, A. B., Schiller, J. H., Gray, R., Dimery, I., Brahmer, J., Samant, M., Wang, L. I., Johnson, D. H. (2009). Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non-Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab. JCO 27: 1405-1412 [Abstract] [Full Text]
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C. (2009). Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL. JCO 27: 1227-1234 [Abstract] [Full Text]
Ruan, J., Hajjar, K., Rafii, S., Leonard, J. P. (2009). Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 20: 413-424 [Abstract] [Full Text]
de Boer, R., Humblet, Y., Wolf, J., Nogova, L., Ruffert, K., Milenkova, T., Smith, R., Godwood, A., Vansteenkiste, J. (2009). An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol 20: 486-491 [Abstract] [Full Text]
Gressett, S. M, Shah, S. R (2009). Intricacies of Bevacizumab-Induced Toxicities and Their Management. The Annals of Pharmacotherapy 43: 490-501 [Abstract] [Full Text]
Zinner, R. G., Barrett, B. L., Popova, E., Damien, P., Volgin, A. Y., Gelovani, J. G., Lotan, R., Tran, H. T., Pisano, C., Mills, G. B., Mao, L., Hong, W. K., Lippman, S. M., Miller, J. H. (2009). Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Molecular Cancer Therapeutics 8: 521-532 [Abstract] [Full Text]
Cao, Y. (2009). Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands. Sci Signal 2: re1-re1 [Abstract] [Full Text]
Hambley, T. W., Hait, W. N. (2009). Is Anticancer Drug Development Heading in the Right Direction?. Cancer Res. 69: 1259-1262 [Abstract] [Full Text]
CHARPIDOU, A. G., GKIOZOS, I., TSIMPOUKIS, S., APOSTOLAKI, D., DILANA, K. D., KARAPANAGIOTOU, E. M., SYRIGOS, K. N. (2009). Therapy-induced Toxicity of the Lungs: An Overview. Anticancer Res 29: 631-639 [Abstract] [Full Text]
Gridelli, C., Maione, P., Rossi, A., Ferrara, M. L., Bareschino, M. A., Schettino, C., Sacco, P. C., Ciardiello, F. (2009). Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?. The Oncologist 14: 137-147 [Abstract] [Full Text]
Crabb, S. J., Patsios, D., Sauerbrei, E., Ellis, P. M., Arnold, A., Goss, G., Leighl, N. B., Shepherd, F. A., Powers, J., Seymour, L., Laurie, S. A. (2009). Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non-Small-Cell Lung Cancer. JCO 27: 404-410 [Abstract] [Full Text]
Riely, G. J., Rizvi, N. A., Kris, M. G., Milton, D. T., Solit, D. B., Rosen, N., Senturk, E., Azzoli, C. G., Brahmer, J. R., Sirotnak, F. M., Seshan, V. E., Fogle, M., Ginsberg, M., Miller, V. A., Rudin, C. M. (2009). Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non-Small-Cell Lung Cancer. JCO 27: 264-270 [Abstract] [Full Text]
Kamp, D. W. (2009). Drug-Induced Lung Diseases. ACCP Pulmonary Med Brd Rev 25: 319-344 [Full Text]
Coxon, A., Bush, T., Saffran, D., Kaufman, S., Belmontes, B., Rex, K., Hughes, P., Caenepeel, S., Rottman, J. B., Tasker, A., Patel, V., Kendall, R., Radinsky, R., Polverino, A. (2009). Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors. Clin. Cancer Res. 15: 110-118 [Abstract] [Full Text]
Hirata, D., Yamabuki, T., Miki, D., Ito, T., Tsuchiya, E., Fujita, M., Hosokawa, M., Chayama, K., Nakamura, Y., Daigo, Y. (2009). Involvement of Epithelial Cell Transforming Sequence-2 Oncoantigen in Lung and Esophageal Cancer Progression. Clin. Cancer Res. 15: 256-266 [Abstract] [Full Text]
Scagliotti, G. V., Ceppi, P., Novello, S., Papotti, M. (2009). Chemotherapy Treatment Decisions in Advanced Non-small Cell Lung Cancer Based on Histology. Am Soc Clin Oncol Ed Book 2009: 431-435 [Abstract] [Full Text]
Evans, T. L. (2009). Novel, Targeted Agents with Thoracic Radiation in the Treatment of Locally Advanced Non-small Cell Lung Cancer. Am Soc Clin Oncol Ed Book 2009: 445-449 [Abstract] [Full Text]
Yang, S. X., Swain, S. M. (2009). Reply to the Letter to the Editor from Jubb. Clin. Cancer Res. 15: 414-414 [Full Text]
Kim, H.-T., Lee, J.-E., Shin, E.-S., Yoo, Y.-K., Cho, J.-H., Yun, M.-H., Kim, Y.-H., Kim, S.-K., Kim, H.-J., Jang, T.-W., Kwak, S.-M., Kim, C.-S., Ryu, J.-S. (2008). Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. JCO 26: 5972-5979 [Abstract] [Full Text]
Lee, F. Y.F., Covello, K. L., Castaneda, S., Hawken, D. R., Kan, D., Lewin, A., Wen, M.-L., Ryseck, R.-P., Fairchild, C. R., Fargnoli, J., Kramer, R. (2008). Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models. Clin. Cancer Res. 14: 8123-8131 [Abstract] [Full Text]
Ma, J., Waxman, D. J. (2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Molecular Cancer Therapeutics 7: 3670-3684 [Abstract] [Full Text]
Dickler, M. N., Rugo, H. S., Eberle, C. A., Brogi, E., Caravelli, J. F., Panageas, K. S., Boyd, J., Yeh, B., Lake, D. E., Dang, C. T., Gilewski, T. A., Bromberg, J. F., Seidman, A. D., D'Andrea, G. M., Moasser, M. M., Melisko, M., Park, J. W., Dancey, J., Norton, L., Hudis, C. A. (2008). A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer. Clin. Cancer Res. 14: 7878-7883 [Abstract] [Full Text]

Comments and questions? Please contact us.